The Untranslated 3'End of SARS-CoV-2 RNA as a Determinant of Obesity-Accelerated Infectivity

SARS-CoV-2 RNA 的非翻译 3 末端是肥胖加速感染的决定因素

基本信息

  • 批准号:
    10318871
  • 负责人:
  • 金额:
    $ 40.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-14 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Obesity is an epidemic-scale problem in the U.S. affecting about 35% of the adult population, and is a major risk factor for the ongoing pandemic, COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the RNA betacoronavirus that is the causative agent of COVID-19. Despite rapid progress in developing effective vaccines, progress in devising improved therapeutics has been slow, and there is an urgent need for anti-viral therapeutics for treatment of infected patients not protected by vaccines. Certain demographics are variably resistant to vaccination, for example, obesity markedly reduces effectiveness of several vaccines. Therapeutics can also be critical in the eventuality that mutations in the virus render the vaccine ineffective. The molecular events responsible for expression of SARS-CoV-2 proteins are known from studies of other betacoronaviruses; however, the regulatory pathways and pathological conditions determining their expression are poorly understood. The translation of viral RNA utilizes the host mRNA translation machinery, primarily regulated by specific RNA-binding proteins or complexes that bind sequence or structural elements in terminal non-coding regions. Importantly, the coding regions of SARS-CoV-2 genomic RNA and the ten subgenomic mRNAs (sgmRNAs) are likewise bordered by non-coding upstream and downstream regions, termed the 5'- leader and 3'-end sequences, respectively. A critical feature of the genome and the sgmRNAs of SARS-CoV-2 is that identical 5'-leader and 3'-end sequences are present in all. Thus, the terminal sequences represent novel, unexplored targets for interference with virus assembly and function. We have discovered a 39-nt sequence in the 3'-end of SARS-CoV-2 bearing structural similarity to the GAIT (interferon-gamma-activated inhibitor of translation) RNA element previously described by us. We show that glutamyl-prolyl tRNA synthetase (EPRS) a protein that binds the human GAIT element also binds the vGLE. Moreover, IFN-γ, a pro-inflammatory cytokine, and insulin, an obesity-induced hormone, markedly increases expression of a luciferase reporter bearing the intact vGLE. These results are the first to show a functional consequence of an RNA element in the 3'-end sequence of SARS-CoV-2. We hypothesize that binding of EPRS to the vGLE stimulates sgmRNA translation required for expression of structural and other SARS-CoV-2 proteins, and for programmed ribosomal frameshifting required for genome replication. We will test this hypothesis by pursuing two Specific Aims: In Aim 1 we elucidate the role of EPRS binding to the SARS-CoV-2 3'UTR vGLE in regulating viral replication and sgmRNA translation. In Aim 2 we develop RNA inhibitors that target EPRS/vGLE interactions and block viral protein expression. We anticipate these fundamental studies will provide the first information on the function of the 3'-end of SARS-CoV-2, and will provide a foundation for development of therapeutic agents to be used in combination with mechanistically distinct anti-viral agents targeting the vGLE and possibly emerging betacoronaviruses.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAUL L FOX其他文献

PAUL L FOX的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAUL L FOX', 18)}}的其他基金

The mammalian multi-tRNA synthetase complex
哺乳动物多tRNA合成酶复合物
  • 批准号:
    10331178
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
The Untranslated 3'End of SARS-CoV-2 RNA as a Determinant of Obesity-Accelerated Infectivity
SARS-CoV-2 RNA 的非翻译 3 末端是肥胖加速感染的决定因素
  • 批准号:
    10689137
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
The mammalian multi-tRNA synthetase complex
哺乳动物多tRNA合成酶复合物
  • 批准号:
    10531618
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Adipokines, Aging, and Alzheimers Disease
脂肪因子、衰老和阿尔茨海默病
  • 批准号:
    10177836
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Assay Development for Discovery of a Small Molecule Inhibitor of a Novel Metabolic Pathway that Drives Obesity
发现导致肥胖的新型代谢途径的小分子抑制剂的检测方法开发
  • 批准号:
    10320035
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Adipokines, Aging, and Alzheimers Disease
脂肪因子、衰老和阿尔茨海默病
  • 批准号:
    10378046
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Assay Development for Discovery of a Small Molecule Inhibitor of a Novel Metabolic Pathway that Drives Obesity
发现导致肥胖的新型代谢途径的小分子抑制剂的检测方法开发
  • 批准号:
    10115720
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Adipokines, Aging, and Alzheimers Disease
脂肪因子、衰老和阿尔茨海默病
  • 批准号:
    10601044
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Multisite phosphorylated S6K1 directs a regulatory module determining adipocyte lipid metabolism
多位点磷酸化 S6K1 指导决定脂肪细胞脂质代谢的调节模块
  • 批准号:
    10349543
  • 财政年份:
    2020
  • 资助金额:
    $ 40.25万
  • 项目类别:
Macromolecular Interaction Core
高分子相互作用核心
  • 批准号:
    8242738
  • 财政年份:
    2011
  • 资助金额:
    $ 40.25万
  • 项目类别:

相似国自然基金

3'-甲氧基葛根素生物合成途径中关键甲基转移酶基因的克隆与功能分析
  • 批准号:
    31300258
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
  • 批准号:
    81300507
  • 批准年份:
    2013
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
3'-UTR单核苷酸多态性影响CYP8B1基因表达致胆囊胆固醇结石形成的机制研究
  • 批准号:
    81370561
  • 批准年份:
    2013
  • 资助金额:
    70.0 万元
  • 项目类别:
    面上项目
异源杂交多倍化鲫鲤特有性状的转录组及后转录组水平变化规律研究
  • 批准号:
    31360514
  • 批准年份:
    2013
  • 资助金额:
    54.0 万元
  • 项目类别:
    地区科学基金项目
HIF基因3'UTR区SNP参与胰腺癌HIF-1α表达调控的分子机制及功能研究
  • 批准号:
    81302082
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
鼻咽癌转移相关通路分子的microRNA调控机制及3'UTR区可变剪切的作用研究
  • 批准号:
    81372886
  • 批准年份:
    2013
  • 资助金额:
    70.0 万元
  • 项目类别:
    面上项目
小鼠精原干细胞中APA位点研究及3'UTR使用频率数据库构建
  • 批准号:
    31301085
  • 批准年份:
    2013
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了